AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric ...
The Company is investigating novel molecules within the CYB005 program at non-hallucinogenic doses for a range of Central Nervous System (“CNS”) disorders. In addition, the Company is continuing to ...
Healthline team member Heather Riesebeck has tried several treatments ... and more tame bursts of anxiety during the day. Another tester who has generalized anxiety disorder took them in the ...